KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Change in Cash (2020 - 2025)

Ginkgo Bioworks Holdings (DNA) has disclosed Change in Cash for 4 consecutive years, with -$105.0 million as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Change in Cash fell 536.35% year-over-year to -$105.0 million, compared with a TTM value of -$380.0 million through Dec 2023, down 70.14%, and an annual FY2025 reading of -$393.4 million, down 2.48% over the prior year.
  • Change in Cash was -$105.0 million for Q4 2023 at Ginkgo Bioworks Holdings, down from -$77.4 million in the prior quarter.
  • Across five years, Change in Cash topped out at $1.5 billion in Q3 2021 and bottomed at -$172.4 million in Q4 2021.
  • Average Change in Cash over 4 years is $39.6 million, with a median of -$77.4 million recorded in 2023.
  • The sharpest move saw Change in Cash surged 113.96% in 2022, then plummeted 536.35% in 2023.
  • Year by year, Change in Cash stood at -$88.4 million in 2020, then plummeted by 95.08% to -$172.4 million in 2021, then surged by 113.96% to $24.1 million in 2022, then tumbled by 536.35% to -$105.0 million in 2023.
  • Business Quant data shows Change in Cash for DNA at -$105.0 million in Q4 2023, -$77.4 million in Q3 2023, and -$86.6 million in Q2 2023.